Profile data is unavailable for this security.
About the company
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer. It has commenced a Phase III clinical trial, Flamingo-01 an immunotherapy to prevent breast cancer recurrences.
- Revenue in USD (TTM)0.00
- Net income in USD-8.89m
- Incorporated2006
- Employees3.00
- LocationGreenwich Lifesciences Inc3992 Bluebonnet Dr, Building 14STAFFORD 77477United StatesUSA
- Phone+1 (203) 434-3290
- Fax+1 (302) 636-5454
- Websitehttps://greenwichlifesciences.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alimera Sciences Inc | 80.75m | -21.39m | 167.60m | 159.00 | -- | 3.63 | -- | 2.08 | -2.16 | -2.16 | 3.17 | 0.8819 | 0.8235 | 6.22 | 2.98 | 507,886.80 | -20.53 | -19.08 | -29.94 | -27.37 | 86.58 | 86.80 | -24.93 | -19.55 | 2.31 | -0.1919 | 0.5835 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
| Vaxart Inc | 8.89m | -81.74m | 169.55m | 109.00 | -- | 3.04 | -- | 19.08 | -0.5431 | -0.5431 | 0.059 | 0.3155 | 0.0813 | -- | 21.67 | 81,513.76 | -74.81 | -49.60 | -86.63 | -54.86 | -- | -- | -920.00 | -1,398.00 | -- | -- | 0.0705 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| Scpharmaceuticals Inc | 17.63m | -57.71m | 171.26m | 135.00 | -- | 6.97 | -- | 9.71 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
| Achieve Life Sciences Inc | 0.00 | -27.32m | 171.26m | 22.00 | -- | 3.46 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Kodiak Sciences Inc | 0.00 | -232.75m | 173.37m | 107.00 | -- | 0.7186 | -- | -- | -4.44 | -4.44 | 0.00 | 4.59 | 0.00 | -- | -- | 0.00 | -43.30 | -31.73 | -47.44 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Lifecore Biomedical Inc | 103.27m | -64.24m | 179.31m | 459.00 | -- | -- | -- | 1.74 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
| Greenwich Lifesciences Inc | 0.00 | -8.89m | 180.04m | 3.00 | -- | 26.81 | -- | -- | -0.6921 | -0.6921 | 0.00 | 0.5215 | 0.00 | -- | -- | 0.00 | -86.87 | -36.43 | -89.30 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| Abeona Therapeutics Inc | 3.50m | -76.66m | 181.22m | 84.00 | -- | -- | -- | 51.78 | -3.20 | -3.20 | 0.1461 | -0.3224 | 0.0546 | -- | 2.54 | 41,666.67 | -119.62 | -53.22 | -140.83 | -65.81 | -- | -- | -2,190.26 | -1,894.25 | -- | -- | 1.97 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Outlook Therapeutics Inc | 0.00 | -51.50m | 181.26m | 24.00 | -- | -- | -- | -- | -3.99 | -3.99 | 0.00 | -1.87 | 0.00 | -- | -- | 0.00 | -122.07 | -214.69 | -441.62 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -- | 3.00 | -- | -- | -- | 10.70 | -- | -- | -- |
| OptiNose Inc | 74.02m | -30.75m | 182.50m | 132.00 | -- | -- | -- | 2.47 | -0.2733 | -0.2733 | 0.659 | -0.8777 | 0.7453 | 0.8764 | 4.74 | 560,772.80 | -30.91 | -48.25 | -- | -98.95 | 88.98 | 86.96 | -41.47 | -131.66 | 2.17 | -1.16 | 4.16 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -18.84m | 182.99m | 1.00 | -- | 60.66 | -- | -- | -0.6889 | -0.6889 | 0.00 | 0.1019 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.8986 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Fennec Pharmaceuticals Inc | 44.95m | 2.84m | 190.78m | 36.00 | 192.51 | 63.31 | 67.08 | 4.24 | 0.0366 | 0.0366 | 1.62 | 0.1112 | 0.9878 | 1.15 | 7.52 | -- | 6.25 | -73.43 | 7.37 | -84.32 | 96.19 | -- | 6.33 | -383.28 | 6.72 | 1.84 | 0.9087 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| P3 Health Partners Inc | 1.35bn | -67.27m | 191.09m | 400.00 | -- | 0.4924 | -- | 0.1413 | -0.5855 | -0.5855 | 11.86 | 1.23 | 1.57 | -- | 11.40 | 3,381,965.00 | -21.31 | -- | -90.11 | -- | 1.59 | 0.1781 | -13.57 | -56.93 | -- | -10.05 | 0.2368 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
Data as of May 17 2024. Currency figures normalised to Greenwich Lifesciences Inc's reporting currency: US Dollar USD
4.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 221.85k | 1.72% |
| Degroof Petercam Asset Services SAas of 31 Dec 2022 | 87.00k | 0.68% |
| Millennium Management LLCas of 31 Mar 2024 | 63.81k | 0.50% |
| Geode Capital Management LLCas of 31 Mar 2024 | 58.24k | 0.45% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 55.51k | 0.43% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 41.51k | 0.32% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 37.50k | 0.29% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 35.87k | 0.28% |
| Jane Street Capital LLCas of 31 Mar 2024 | 20.64k | 0.16% |
| Qube Research & Technologies Ltd.as of 31 Mar 2024 | 17.32k | 0.13% |
More ▼
Data from 28 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
